For users without scalp irritation, most users report nothing perceptible during application or in the hours afterward. The molecule is not psychoactive, has no systemic anti-androgen effect at design-intent doses, and produces no acute physiological signature.

Effects on hair appear over months at a slower tempo than RU58841 in community comparisons:

• Weeks 1-4: Possible mild "shed" phase as miniaturized follicles synchronize — less prominent than minoxidil/RU58841 shed, often absent.
• Months 2-3: Stabilization of progression; subtle density gains visible on photos but not in mirror.
• Months 4-6: Vellus-to-terminal transitions; modest density improvement at temples and vertex in responders; full effect plateauing.
• Months 6-12: Effect size in responders; the Sovak 2002 trial measured at 3 months, showing the effect direction but probably underestimating long-term ceiling.
• Discontinuation: Effect reverses over ~3-6 months as DHT regains AR access. No "lock-in" of regrown follicles — chronic-use molecule, like all hair-loss drugs except hair transplantation.

Adverse subjective effects (when they occur):

• Scalp itch, redness, mild flaking — vehicle-dependent (Eucapil uses ethanol-based vehicle); often improved by spacing applications or letting scalp recover.
• Headache, fatigue, libido changes — not reported in the Sovak 2002 trial, not reported in Czech/Slovak pharmacovigilance, and not a recurring theme in research-chem user logs at design-intent doses. Absence of these signals is the cleanest evidence that the self-quenching design works in practice.

• Tolerance buildup: No published evidence of tolerance to AR antagonism with chronic use; Eucapil is a continuous-use product.
• Recommended cycle: None. Daily continuous is the operating model.
• Reset protocol if needed: N/A — discontinuation simply lets AR signaling return and miniaturization resume.

Synergistic with

• Minoxidil (topical, 2-5%): Standard hair-loss community pairing. Different mechanisms (AR blockade vs. anagen extension / vasodilation), no PK interaction, often combined in same daily regimen with minoxidil applied first and allowed to dry fully before topilutamide. Mechanistic A-tier rationale, modest anecdotal support.
• Finasteride or dutasteride (oral): Mechanistically complementary (lower DHT systemically + block residual AR locally) but the typical topilutamide user is avoiding the systemic 5αRI profile. Most do not stack. For users already on a 5αRI who tolerate it, adding topilutamide may produce marginal additional benefit at marginal additional cost.
• Topical anti-inflammatory adjuncts (azelaic acid, ketoconazole 2% shampoo) — for the inflammatory component of AGA. No interaction; possibly modestly synergistic.
• Microneedling (dermaroller 0.5-1.5 mm 1-2×/week): Mechanically increases drug penetration; community-favored adjunct. Caveat with topilutamide specifically: because the molecule is designed to hydrolyze on contact with aqueous fluid, deep-penetration delivery may shift the balance away from local AR binding and toward faster systemic-circulation hydrolysis. Net effect on efficacy is unclear; light microneedling probably fine, aggressive microneedling may reduce topilutamide effect compared to RU58841.

Avoid stacking with

• Topical testosterone or any topical androgen application near the scalp — defeats the purpose by saturating local AR.
• Other topical AR antagonists (clascoterone / Winlevi, RU58841) without specific reason — receptor-saturation overlap with no additional benefit, more irritation risk.
• DMSO penetration-enhanced vehicles — pushes more drug systemically before hydrolysis can deactivate it; undermines the entire safety design.

Neutral / safe co-administration

• Standard supplement stack (omega-3, magnesium, NAC, citicoline, theanine, rhodiola, curcumin, creatine, beta-alanine, vitamin D3, vitamin C, glycine, phosphatidylserine) — no interaction.
• Caffeine, modafinil, bromantane, Russian peptides — no interaction.

• CYP enzymes: Limited published data. Hydrolysis-mediated deactivation suggests minimal CYP involvement at design-intent doses. The closely related anilide-class anti-androgens (flutamide, bicalutamide) are CYP3A4 substrates and weak CYP3A4 inhibitors; topilutamide at therapeutic topical doses should not produce clinically meaningful CYP impact, but heavy use or compromised barrier could shift this.
• No clinically significant documented interactions at standard topical use, in part because topilutamide has not been part of a regulatory drug-interaction studies program outside Czechia.
• Theoretical concerns: Concomitant systemic AR antagonists (bicalutamide, abiraterone, enzalutamide), strong CYP3A4 inhibitors (azoles, macrolides) if substantial absorption — none applicable to typical AGA users.

• AR gene CAG repeat polymorphism: Shorter CAG repeats → more sensitive AR → more aggressive AGA pattern. Theoretically may also modulate response to topilutamide (more receptor blockade required), but unstudied.
• 5α-reductase type II (SRD5A2) variants: Affect DHT production but not directly topilutamide mechanism (which is downstream).
• CYP3A4 / CYP2D6: Could modulate metabolism of any topilutamide that escapes systemic hydrolysis, but the hydrolytic pathway is non-CYP, so this matters less than for RU58841.
• Practical note: No genetic test informs topilutamide dosing today. This user's 23andMe (~June 2026) will include AR-related calls, but they are informational, not actionable for this molecule.

Reality check on research-chem sourcing: Topilutamide is sold by overlapping vendor lists with RU58841 and CB-03-01 (clascoterone). The molecule's hydrolytic lability is the underappreciated quality-control variable — a bottle stored at high temperature for shipping or in a hot bathroom may already have degraded to inactive metabolites before the user opens it. Storage and freshness matter substantially more than for RU58841.

Eucapil import path is straightforward for users with Czech/Slovak pharmacy access; for US/UK importers, customs is generally permissive of small personal-use quantities of OTC-equivalent products, but the legal posture is gray.

This user's sourcing comfort is research-chem-friendly, so this is solvable when needed. The harder question is timing — there is no value in solving the sourcing puzzle before the indication exists.

• Baseline (before starting): Standardized photo series (Hamilton-Norwood standardized angles), scalp dermoscopy/phototrichogram if available, total testosterone, free testosterone, LH, FSH, SHBG, estradiol (sensitive assay), prolactin, ALT/AST. For this user: irrelevant until an indication appears, but the June 2026 baseline panel covers most of these regardless.

• During use:

  • Photo series at month 3, 6, 12, then annually.
  • Hormone panel (T, LH, FSH, E2, prolactin) at month 6 and annually if any systemic-feeling symptoms appear (which would be unexpected per the design).
  • LFTs at month 6 if heavy use or if extending to non-standard concentrations/vehicles.
  • Symptom diary (libido, mood, energy, scalp condition).

• Post-cycle (if discontinued): N/A for chronic use.